Liquidia (LQDA) stock

Lung medicines , market cap $4.0B

Medicines for pulmonary hypertension

Worth $4.0B

Pre-market

$46.00

+3.60%

Close $44.40 -0.20%

As of 8:42 AM ET pre-market, delayed 15+ min · Live for Pro members

Quality Score

Below Average

In its industry

#30of 90

Pharma

Checks firing

3of 14

Transition

From 52-week high

-52.6%

under its best in a year

LQDA's Quality Score rose 1 point on Fri, Nov 6, to 5. It had its calmest day in a week.

Follow LQDA's trial news. Pro members can get an alert when Liquidia files news, and see its trials, share raises, and its CEO's filings.

Get an alert when LQDA files news on its trialsSee it live, free until tomorrow morning. No account. No card. Then keep going with a free account.

We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.

Why is LQDA down?

Down 51% from Aug 10 to Nov 6.

Our sources do not explain the slide.
The S&P 500 fell 4.9% over the same days.

Sources: Price history, Nov 6, 2026

−2Insider trades selling into the 52-week low: Stephen M. Bloch (Director) sold $6.4M on Oct 5, and 4 more filings

1 more thing pulling LQDA's score down, for Pro members.

Get an alert when LQDA's Quality Score turns up →

Key facts on LQDA

Key facts on LQDA
The company	Sales up 2,234% on the year
Latest filing	8-K, Oct 14 Signed a material agreement and ended a material agreement

1 more reason behind LQDA's 5, free with an account →2 more reasons behind LQDA's 5, for Pro members.

LQDA in the news

ReportReports tomorrow, before the open. Every 3 months, a company tells everyone how much it sold and earned. It rose after 3 of its last 4 reports, +4.8% on average. Past reports ›

Big story

Deal

Liquidia Settles United Therapeutics Suits With $380.7M Deal

LQDA closed +26.6% that day on 7.1x normal volume.

Reported by law360.com · covered by 13 outlets

Get an alert on LQDA's next big story →

Tested. Our top-scored stocks returned 2.2x the average stock over the next month. Reconstructed after the fact; recorded live since Sep 9, 2026. How we tested it

LQDA catalysts

Coming up

After its last 4 reports it closed +4.8% on average, higher 3 of 4 times.

3 past catalysts since 2025, with sizes and sources, for Pro members.

What's next for LQDA

Its trials

A trial underway: Re-SpirePhase 3 · Recruiting · 344 people · main data estimated Jul 2029 · NCT07285655

4 more trials, 55 filings, for Pro members.

Dilution on the horizon

Shelf registration (S-3ASR, filed Mar 5, 2026)

For Pro members: 2 raises and their amounts, and the share count against a year ago.

Insiders

Chief Accounting Officer Dana Boyle sold 1,581 shares on Oct 26, under a planned sale. 88 more insider trades this year.

From Form 4: open-market buys and sales only.

Get an alert when Roger Jeffs buys or sells

For Pro members: every trade, and Roger Jeffs’s 22 filings and quotes.

Get an alert when LQDA files news on its trialsA free account. No card.

See every upcoming FDA date →

FDA dates in the next 60 days

Decision dates and advisory committee meetings the companies have announced in their filings, soonest first and small companies first.

DateStockDrug

In 13 daysFDA decisionIn 13 days · FDA decisionCAPRCapricor TherapeuticsDeramiocelCAPRCapricor Therapeutics · $500MDeramiocelFDA decision due (PDUFA)
In 13 daysFDA decisionIn 13 days · FDA decisionSVRASavaraMolgramostimSVRASavara · $900MMolgramostimFDA decision due (PDUFA)
In 43 daysFDA decisionIn 43 days · FDA decisionMLYSMineralys TherapeuticsLorundrostatMLYSMineralys Therapeutics · $1.3BLorundrostatFDA decision due (PDUFA)

14 more FDA dates and 103 trial data dates in the next 60 days, each on the FDA calendar. Pro members see whether each company's cash lasts past its date, with an optional alert before it. See all 151 dates, ranked →

How LQDA ranks in Pharma

LQDA is #30 of 90 by Quality Score.

How LQDA ranks in Pharma
Rank	Stock	Checks	Quality Score
1	ABBVAbbVie	8/14	24
2	LLYEli Lilly	5/14	18
3	CRONCronos	5/14	18
	LNTHLantheus		Open for its score
	MANEVeradermics		Open for its score
	MGNXMacroGenics		Open for its score
30	LQDALiquidia	3/14	5

Share count against a year before: LQDA +3.9%, UTHR -2.5%.

When does LQDA report earnings, and what happens after?

Reports Tue Nov 10, before the open (tomorrow). Confirmed.

What an earnings report is: every 3 months, a company tells everyone how much it sold and earned. We read the figures, the outlook, and how the stock moved after.

What LQDA reported on Aug 12, 2026

The quarter

The figures are not read from the release yet.

“The increase of $163.9 million was due to higher volume of YUTREPIA sales.”

The filing on EDGAR

Where the sales came from

LQDA's results filing gives no sales by line in a table we read.

The outlook

No outlook figures read from this release.

In the company's words

“The increase of $18.6 million or 48% was primarily due to a $10.0 million increase in personnel expenses and a $3.1 million increase in stock-based compensation driven by higher headcount, and an $8.6 million increase in commercial and consulting expenses to support the commercialization of YUTREPIA.”

From its results filing (SEC filing · Aug 12)

2 more sentences, for Pro members.

The numbers

Market value: $4B; today
Sales: $451M; up 2,234% on the year
Free cash flow: $151M; last 12 months

Its share count grew 12% a year over 3 years.

4 more figures, for Pro members.

No analyst estimates on Breakaway: every figure here is filed.

The whole report on LQDA: every line of its sales, every outlook beside the one it replaced, and the company's words, for Pro members.

Close after the report, last 3

+0.4%+25.6%-10.5%

Mar 5May 11Aug 12

Reported	When	Gap	Reaction	5 days
Aug 12, 2026Before open	Before open	-5.0%	-10.5%	-15.6%
May 11, 2026Before open	Before open	+4.3%	+25.6%	+34.6%
Mar 5, 2026Before open	Before open	-6.9%	+0.4%	+12.2%

LQDA closed higher after 3 of its last 4 reports.

All 4 reports, and LQDA's Quality Score going into each

Everyone reporting earnings this week

LQDA sales and profit by year

Sales and profit by year

Sales grew in four of the last six years, to $158M in 2025. It lost money in each of the seven years.

LQDA has 3 of 14 chart checks firing

Trend1 of 5 shown

MA FAN 21 EMA W.EMA HH/HL 52W HI

Volume1 of 3 shown

VOL VDU U/D VOL

Tight range1 of 3 shown

ATR SQZ SQUEEZE NR7

Buying1 of 3 shown

OBV+CLOSE HI SPRING

The other 10 checks on LQDA, and all 14 on every stock.Get in free →

LQDA RSI on Nov 6: 51.0, below its 50-day and 200-day averages

Not scored

RSI 51.0, MACD above signal, below both averages. Not scored.13 readings

The deep dive on LQDA

What it does and how it makes money3 findings"Under the UNC License, we are also required to pay UNC certain fees other than royalties that we collect and are attributable to UNC sublicensed intellectual property." (10-K for fiscal 2025)SEC filing · Mar 5, 2026
Where it stands3 findingsFor Pro members3 findings on where LQDA stands: its cash, debt, and share count, for Pro members
What changed in its filings6 findings"On April 21, 2025, the Company filed a complaint for patent infringement against United Therapeutics in the U.S. District Court for the Middle District of North Carolina (Case No. 1:25-cv-00299) (the '‘494 Patent Litigation') …" (10-Q for the quarter to Jun 30, 2026)SEC filing · Aug 12, 2026New in its "Risk Factors" this year: "Treprostinil SMI, a version of inhaled treprostinil being developed by United Therapeutics as a soft mist inhaler." (10-K for fiscal 2025)SEC filing · Mar 5, 2026
Who holds and trades it4 findingsFor Pro members4 findings on who holds and trades LQDA, for Pro members
Against its closest peers1 peerShare count against a year before: LQDA +3.9%, UTHR -2.5%.

13 more findings on LQDA, each with its source, for Pro members.

LQDA share count over time

Shares: 3.9% more than a year ago (to Jun 30).

Shares of LQDA outstanding, as filed
Shares outstanding	As of
89.5M	Jul 29, 2026
88.9M	May 1, 2026
88.1M	Feb 17, 2026
87M	Oct 20, 2025

Offerings, shelves, and splits of LQDA, from its filings
From its filings	Filed
Registered shares for a later sale (S-3ASR)	Mar 5, 2026
Registered shares for a later sale (S-3)	Mar 19, 2025
Raised $57.5M in a sale of shares, about 1% of its market value	Sep 11, 2024
Registered shares for a later sale (S-3)	Jun 27, 2024

LQDA insider trades

5 insiders sold $130M across 52 filings in the last 6 months. No open-⁠market buys on record. The newest:

SellStephen M. Bloch$6.4MDirectorat $27.13 on Oct 5, filed Oct 7

SellStephen M. BlochDirector$6.4Mat $27.13 on Oct 5, filed Oct 7

All 52 insider filings on LQDA from the last six months, for Pro members.

All LQDA insider trades

LQDA trades by Congress and the executive branch

4 trades disclosed in the last six months. The newest:

SellDonald Trump$15K to $50KPresident (R)traded Aug 31, disclosed Oct 8(38 days later)

SellDonald TrumpPresident (R)$15K to $50Ktraded Aug 31, disclosed Oct 8(38 days later)

All 4 trades on LQDA disclosed by Congress and the executive branch, for Pro members.Get in free →

See what Congress is buying across the market

LQDA's officers and directors

Officers and directors with a Form 4 in the last 12 months.

Roger JeffsChief Executive Officer · 26 trades
Michael KasetaCFO and COO · 10 trades
Jason AdairChief Business Officer · 12 trades
Sarah KreppChief Human Resource Officer · 10 trades
Dana BoyleChief Accounting Officer · 10 trades
Scott MoomawChief Commercial Officer · 8 trades
Rajeev SaggarChief Medical Officer · 7 trades
Russell SchundlerGeneral Counsel · 6 trades

10 more officers and directors file at LQDA.

See insider trades by person

Which ETFs hold LQDA?

In ETFs: LQDA is under 0.1% of VTI, the most of the 24 funds Breakaway covers, by their holdings as filed for Jun 30, 2026.

About Liquidia

Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also conducting studies on L606, an investigational, liposomal formulation of treprostinil.

216 employeesMorrisville, NCliquidia.com

What Liquidia says it competes with

“The pharmaceutical industry is intensely competitive, subject to rapid and significant technological change and places emphasis on the value of proprietary products.”

From its annual report, SEC filing · Mar 5, 2026

Here is what Pro members see.

The same page for Pro members, on Microsoft
Its Quality Score and rank, the line that drives it, and the live price.
The full chart
A year of candles to start, out to the whole history, with insider trades marked and the Quality Score under the price.
Every line of the score
Price action, the company, and signals, each with its points, on LQDA and every other stock.
FDA dates, counted down
Each date in the company's words, its cash against the date, and an optional alert before it.
CEOs buying their own stock
Every CEO buy, biggest names first. Sort, filter, save the list, and set optional alerts.
Congress trades
A member's trades, newest first, each with its amount. Sort and filter the whole list.
14 chart checks, read for you
The ones firing on the stock, each in plain words, its rule a tap away.
Earnings, week by week
Who reports each day, and how each stock took its last four reports.
The market map
Every stock a box, colored by its Quality Score.
Themes, ranked live
Each theme's stocks ranked by Quality Score, live. Here, AI chips.
The top 10, every day
The ten highest Quality Scores at each close, kept day by day, week by week.
Optional alerts, your way
Pick a stock, a score, a price, a filing, or a whole scan. It tells you by push or email.
Your watchlist, scored
Your stocks by Quality Score, today's move, or name.
On your phone and your laptop
The same account and watchlist on both, each laid out for its screen.

Prices refresh every 2.5 seconds during market hours.
Optional alerts by push, email, or the bell.
Add it to your Home Screen and it opens like an app.

Pro members see every line of every stock's score.

What would turn LQDA's score around: 4 things
9 more filings explained, a plain line each
Real-⁠time prices, no delay

BreakawayAug 22Donald Trump bought LQDA$50K to $100K, disclosed Aug 22

Alerts are optional.

See LQDA's 14 chart checks

See it live, free until tomorrow morning. No account. No card. Then keep going with a free account.

Straight AnswersStraight Answers

As of Nov 9, 2026: LQDA's Quality Score is 5 (Below Average), #30 of 90 in Pharma. Insiders sold $130M in the last 6 months (Form 4).

What does LQDA's Quality Score say?

LQDA scores 5 today, which Breakaway calls Below Average. It is #30 of 90 in Pharma by Quality Score, with 3 of 14 chart checks firing. Down 51% from Aug 10 to Nov 6. Breakaway does not say whether to buy any stock: the score does not know your situation, and it is not a recommendation to buy or sell anything. Please do your own research.

What is LQDA's Quality Score?

LQDA scores 5 today, which Breakaway calls Below Average (0 to 5). That is #30 of 90 in Pharma by Quality Score. The score adds up the chart checks, the trend, the company's filed sales, its profits, the news, insider trades, and Congress trades. The section above lists the lines behind LQDA's 5.

Are insiders buying LQDA?

5 insiders sold $130M across 52 filings in the last 6 months. No open-⁠market buys on record. The newest is Stephen M. Bloch, Director, who sold $6.4M on Oct 5. Every filing, with the scored weight, for Pro members.

Are the prices delayed?

Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.